<DOC>
	<DOCNO>NCT01695239</DOCNO>
	<brief_summary>This study ass safety efficacy ixekizumab ( LY2439821 ) compare placebo participant active psoriatic arthritis .</brief_summary>
	<brief_title>A Study Ixekizumab Participants With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Presents establish diagnosis active psoriatic arthritis least 6 month , currently meet Classification Psoriatic Arthritis ( CASPAR ) criterion Active psoriatic arthritis ( PsA ) define presence least 3 tender least 3 swollen joint Presence active psoriatic skin lesion personal history plaque psoriasis ( Ps ) Men must agree use reliable method birth control remain abstinent study Women must agree use reliable birth control remain abstinent study least 12 week stop treatment Current prior use biologic agent treatment Ps PsA Inadequate response great equal 4 conventional diseasemodifying antirheumatic drug ( DMARDs ) Current use one conventional DMARD Evidence active inflammatory arthritic syndrome spondyloarthropathies PsA Have participate study interleukin 17 ( IL17 ) antagonist , include ixekizumab Serious disorder illness psoriatic arthritis Serious infection within last 3 month Breastfeeding nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>